Literature DB >> 29141377

[The clinical significance of anti- ubiquitin C-terminal hydrolase L1 autoantibodies in the diagnosis of neuropsychiatric systemic lupus erythematosus].

Y Meng1, H Sun, J J Xu, R Li, Y Wang.   

Abstract

Objective: To analyze the clinical significance of anti- ubiquitin C-terminal hydrolase L1(UCHL-1)autoantibodies in neuropsychiatric systemic lupus erythematosus (NPSLE).
Methods: Autoantibodies in cerebrospinal fluid specimen of 56 inpatients were detected by using indirect enzyme-linked immunosorbent assay (ELISA) and the fullmedical history and clinical manifestations were analyzed retrospectively.
Results: The levels of anti-UCHL-1 autoantibodies in NPSLE group were significant higher than that in other controls (P<0.05). The positive rate of anti-UCHL-1 autoantibodies in NPSLE group was 23.7% (9/38), which was higher than that in the control groups (0%). A significant difference of anti-UCHL-1 autoantibodies was observed in the patients with blood system involvement (P=0.012). The positive rates of anti-UCHL autoantibodies in the patients with negative SLE related autoantibodies including AnuA, anti-dsDNA, Acl, anti-nRNP, anti-rRNP and anti-Smantibody negative were 41.7%, 29.4%, 29.2%, 25.9%, 25.0%, 25.0%, respectively.The levels of anti-UCHL-1 autoantibodies had a positive correlation with 24-hours proteinuria (r=0.361, P=0.039).
Conclusion: Anti-UCHL-1 autoantibodies had promising value in the diagnosis of neuropsychiatric systemic lupus erythematosus.

Entities:  

Keywords:  Anti- ubiquitin C-terminal hydrolase L1 antibody; Indirect enzyme-linked immunosorbent assay; Neuropsychiatric systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 29141377     DOI: 10.3760/cma.j.issn.0376-2491.2017.42.009

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

Review 1.  Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.

Authors:  Gongjun Tan; Binila Baby; Yuqiu Zhou; Tianfu Wu
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.